Charcot-Marie-Tooth Association Company Profile

20:27 EST 18th November 2017 | BioPortfolio

News Articles [549 Associated News Articles listed on BioPortfolio]

Acceleron starts Phase II trial of ACE-083 to treat Charcot-Marie-Tooth disease

Acceleron Pharma Announces First Patient Treated In Phase II Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease

  Life Sciences Jobs   ...

PHARNEXT Amends The Protocol Of The International Pivotal Phase III Trials Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A

  Life Sciences Jobs   ...

PHARNEXT Announces That The Recommends Continuing The Ongoing Phase III Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A

  Life Sciences Jobs   ...

Charcot–Marie–Tooth disease type 2A with an autosomal-recessive inheritance: the first report of an adult-onset disease

Pharnext Amends the Protocol of the International Pivotal Phase 3 Trials of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

- No safety concern and PXT3003 development milestones remain unchanged - Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 ALPHA), a biopharmaceutical company pioneering a new approach to...

Pharnext ändert das Protokoll der internationalen Phase-3-Zulassungsstudien mit PXT3003 zur Behandlung der Charcot-Marie-Tooth-Erkrankung Typ 1A

- Keine Sicherheitsbedenken und die Entwicklungsmeilensteine zu PXT3003 bleiben unverändert - Pharnext SA (Paris:ALPHA) (FR00111911287 ALPHA), ein biopharmazeutisches Unternehmen mit einem neuarti...

Acceleron begins dosing in Phase II trial of ACE-083 to treat CMT

Acceleron Pharma has started dosing patients in a Phase II clinical trial of its therapeutic candidate ACE-083 for the treatment of Charcot-Marie-Tooth disease (CMT) patients.

PubMed Articles [1573 Associated PubMed Articles listed on BioPortfolio]

Charcot-Marie-Tooth Disease Type 1A: Influence of Body Mass Index on Nerve Conduction Studies and on the Charcot-Marie-Tooth Examination Score.

Charcot-Marie-Tooth Disease type 1A (CMT1A) is caused by a duplication of the peripheral myelin protein gene 22 at chromosome 17p11.2-12. There is limited data regarding whether body mass index (BMI) ...

Natural history of Charcot-Marie-Tooth disease during childhood.

To determine the rate of disease progression in a longitudinal natural history study of children with Charcot-Marie-Tooth disease (CMT).

Genetic and clinical characteristics of NEFL-related Charcot-Marie-Tooth disease.

To analyse and describe the clinical and genetic spectrum of Charcot-Marie-Tooth disease (CMT) caused by mutations in the neurofilament light polypeptide gene (NEFL).

Charcot-Marie-Tooth Disease and Other Genetic Polyneuropathies.

Genetic polyneuropathies are rare and clinically heterogeneous. This article provides an overview of the clinical features, neurologic and electrodiagnostic findings, and management strategies for Cha...

Different nerve ultrasound patterns in Charcot-Marie-Tooth types and HNPP.

Nerve ultrasound in Charcot-Marie-Tooth disease (CMT) has mostly focused on upper limbs. We performed an evaluation of a large cohort of CMT patients in which we sonographically characterized nerve ab...

Clinical Trials [1648 Associated Clinical Trials listed on BioPortfolio]

Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611)

The purpose of this study is to develop and validate a clinical outcome measure to evaluate disability and disease progression of children 3 years of age and younger (infants and toddlers)...

Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease

The object of this research is to test the effectiveness of Coenzyme Q10 (CoQ10) on symptoms of weakness, fatigue, and pain in persons with Charcot-Marie-Tooth disease (CMT).In this study ...

Follow up and Observation of Charcot Marie Tooth Disease in Families

The study is aimed to test the hypothesis that there is anticipation in CMT

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with CMT1 and CMTX, to be condu...

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary study CLN-PXT3003-02, i.e. 15-month double-blind treatment with PXT3003 or placebo, will be eligi...

Companies [1284 Associated Companies listed on BioPortfolio]

Charcot-Marie-Tooth Association

Hereditary Neuropathy Foundation

Hereditary Neuropathy Foundation (HNF) is a non-profit 501(c)3 organization whose mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth disease (CMT) and ...

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. P...

Ella Marie Foundation

The Ella Marie Foundation was founded in 1998 with a simple desire of helping others. Over the past 16 years, that mission has expanded into a cohesive effort to enhance the lives...

Marie Claire

More Information about "Charcot-Marie-Tooth Association" on BioPortfolio

We have published hundreds of Charcot-Marie-Tooth Association news stories on BioPortfolio along with dozens of Charcot-Marie-Tooth Association Clinical Trials and PubMed Articles about Charcot-Marie-Tooth Association for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Charcot-Marie-Tooth Association Companies in our database. You can also find out about relevant Charcot-Marie-Tooth Association Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record